TEVA (TEVA PHARMACEUTICAL-SP ADR)

Medical-Generic Drugs, Pharmaceuticals, Consumer, Non-cyclical



Follow these portfolios. With IBKR Asset Management you can see every trade these investors make with their own money & automatically follow them in your own account.

Invest with us or learn why you should choose us

Portfolios in the same sector - sorted by percentage allocation

The Russell 1000 Healthcare Managed Portfolio includes stocks of companies involved in providing medical or health care products, services, technology, or equipment.

Strategy
Index Tracker

This portfolio is new to IBKR Asset Management and does not have 365 days worth of daily performance data required for us to calculate risk metrics.

Sharpe ratio
-
Performance
Risk score
Fees
  • 0.2% fee
  • $5,000 min

The Russell Top 200 Managed Portfolio seeks to invest in the top 200 large-capitalization U.S. equities.

Strategy
Index Tracker

This portfolio is new to IBKR Asset Management and does not have 365 days worth of daily performance data required for us to calculate risk metrics.

Sharpe ratio
-
Performance
Risk score
Fees
  • 0.2% fee
  • $5,000 min

Our Mid Cap portfolio seeks to achieve capital appreciation by primarily investing in small- to mid-sized companies with above average growth potential. Mid-sized companies, according to the manager, are companies whose market capitalizations ranges from $2 billion to $10 billion at the time of purchase. The manager maintains a concentrated portfolio of mid-cap companies traded on US exchanges.

Strategy
Stocks
Sharpe ratio
0.03 365 days
Performance
2.8% 365 days
Risk score
Fees
  • 0.5% fee
  • $10,000 min

The Freedland Healthcare portfolio invests in healthcare-related stocks. It attempts to identify companies with reasonable valuations and good prospects for growth including ones that offer possible dividends to stockholders. These companies will range from drug, device, retail sales, electronic medical record, prescription services, and HMO/hospital companies. While emphasizing mid cap stocks, large cap and smaller capitalization companies may be included as well as emerging medical treatments/technologies. Companies selected for this portfolio are closely monitored.

Strategy
Stocks
Sharpe ratio
1.28 365 days
Performance
24.9% 365 days
Risk score
Fees
  • 1% fee
  • $20,000 min

Sparrow Unconstrained Long/Short Strategy invests across market sectors, industries, and market capitalization ranges. The Sparrow Unconstrained Long/Short Strategy objective is to provide the most efficient risk/reward outcome over time.

Strategy
Stocks
Sharpe ratio
1.67 365 days
Performance
39.6% 365 days
Risk score
Fees
  • 1% fee
  • $50,000 min



Important Information

  1. Past performance is no guarantee of future results.
  2. Periodic and since and the corresponding spark chart is calculated to the most recent month end date.
  3. Benchmark returns have been calculated by IBKR Asset Management using a time-weighted calculation of daily index valuations.
  4. All graph data is as of the end of day for the referenced period, unless otherwise specified.